{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:51:13Z","timestamp":1760921473156,"version":"build-2065373602"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012319","name":"National Center for Global Health and Medicine","doi-asserted-by":"publisher","award":["24A101"],"award-info":[{"award-number":["24A101"]}],"id":[{"id":"10.13039\/100012319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.cyto.2016.07.004","type":"journal-article","created":{"date-parts":[[2016,8,16]],"date-time":"2016-08-16T10:45:52Z","timestamp":1471344352000},"page":"29-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Pretreatment serum levels of interferon-gamma-inducible protein-10 are associated with virologic response to telaprevir-based therapy"],"prefix":"10.1016","volume":"88","author":[{"given":"Yoko","family":"Yamagiwa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai","family":"Asano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youhei","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Korenaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumoto","family":"Murata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Kanto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Mizokami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiko","family":"Masaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"author":"Organization WH","key":"10.1016\/j.cyto.2016.07.004_b0005"},{"issue":"5 Suppl 1","key":"10.1016\/j.cyto.2016.07.004_b0010","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1002\/hep.1840360704","article-title":"Course and outcome of hepatitis C","volume":"36","author":"Hoofnagle","year":"2002","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"5 Suppl 1","key":"10.1016\/j.cyto.2016.07.004_b0015","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1002\/hep.1840360706","article-title":"Natural history of chronic hepatitis C","volume":"36","author":"Seeff","year":"2002","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"9286","key":"10.1016\/j.cyto.2016.07.004_b0020","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.cyto.2016.07.004_b0025","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"New Engl. J. Med."},{"issue":"Suppl 1","key":"10.1016\/j.cyto.2016.07.004_b0030","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/S0168-8278(12)60010-5","article-title":"Antiviral strategies in hepatitis C virus infection","volume":"56","author":"Sarrazin","year":"2012","journal-title":"J. Hepatol."},{"issue":"18","key":"10.1016\/j.cyto.2016.07.004_b0035","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"Telaprevir and peginterferon with or without ribavirin for chronic HCV infection","volume":"360","author":"Hezode","year":"2009","journal-title":"New Engl. J. Med."},{"issue":"18","key":"10.1016\/j.cyto.2016.07.004_b0040","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa0806104","article-title":"Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection","volume":"360","author":"McHutchison","year":"2009","journal-title":"New Engl. J. Med."},{"issue":"25","key":"10.1016\/j.cyto.2016.07.004_b0045","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"New Engl. J. Med."},{"issue":"14","key":"10.1016\/j.cyto.2016.07.004_b0050","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMoa0908014","article-title":"Telaprevir for previously treated chronic HCV infection","volume":"362","author":"McHutchison","year":"2010","journal-title":"New Engl. J. Med."},{"issue":"11","key":"10.1016\/j.cyto.2016.07.004_b0055","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","article-title":"Response-guided telaprevir combination treatment for hepatitis C virus infection","volume":"365","author":"Sherman","year":"2011","journal-title":"New Engl. J. Med."},{"issue":"4","key":"10.1016\/j.cyto.2016.07.004_b0060","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jhep.2008.07.013","article-title":"Treatment predictors of a sustained virologic response in hepatitis B and C","volume":"49","author":"Kau","year":"2008","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.cyto.2016.07.004_b0065","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jhep.2012.05.016","article-title":"Genomics and HCV infection: progression of fibrosis and treatment response","volume":"57","author":"Estrabaud","year":"2012","journal-title":"J. Hepatol."},{"issue":"10","key":"10.1016\/j.cyto.2016.07.004_b0070","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","article-title":"Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C","volume":"41","author":"Tanaka","year":"2009","journal-title":"Nat. Genet."},{"issue":"7262","key":"10.1016\/j.cyto.2016.07.004_b0075","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.cyto.2016.07.004_b0080","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/ng.447","article-title":"IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy","volume":"41","author":"Suppiah","year":"2009","journal-title":"Nat. Genet."},{"issue":"4","key":"10.1016\/j.cyto.2016.07.004_b0085","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2009.12.056","article-title":"Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study","volume":"138","author":"Rauch","year":"2010","journal-title":"Gastroenterology"},{"issue":"7265","key":"10.1016\/j.cyto.2016.07.004_b0090","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nature08463","article-title":"Genetic variation in IL28B and spontaneous clearance of hepatitis C virus","volume":"461","author":"Thomas","year":"2009","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.cyto.2016.07.004_b0095","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/hep.23690","article-title":"Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin","volume":"52","author":"Akuta","year":"2010","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"1","key":"10.1016\/j.cyto.2016.07.004_b0100","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/infdis\/jir210","article-title":"IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C","volume":"204","author":"Chayama","year":"2011","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.cyto.2016.07.004_b0105","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/jgh.12402","article-title":"Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b","volume":"29","author":"Tsubota","year":"2014","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"6021","key":"10.1016\/j.cyto.2016.07.004_b0110","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/315672a0","article-title":"Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins","volume":"315","author":"Luster","year":"1985","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.cyto.2016.07.004_b0115","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1359-6101(97)00015-4","article-title":"The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily","volume":"8","author":"Neville","year":"1997","journal-title":"Cytokine Growth Factor Rev."},{"issue":"3","key":"10.1016\/j.cyto.2016.07.004_b0120","first-page":"121","article-title":"CXCL10\/IP-10 in infectious diseases pathogenesis and potential therapeutic implications","volume":"22","author":"Liu","year":"2011","journal-title":"Cytokine Growth Factor Rev."},{"issue":"3","key":"10.1016\/j.cyto.2016.07.004_b0125","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.autrev.2013.10.010","article-title":"Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases","volume":"13","author":"Antonelli","year":"2014","journal-title":"Autoimmun. Rev."},{"issue":"11","key":"10.1016\/j.cyto.2016.07.004_b0130","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.4049\/jimmunol.158.11.5536","article-title":"Expression of IFN-inducible protein-10 in chronic hepatitis","volume":"158","author":"Narumi","year":"1997","journal-title":"J. Immunol. (Baltimore, Md.: 1950)"},{"issue":"3","key":"10.1016\/j.cyto.2016.07.004_b0135","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1189\/jlb.0303093","article-title":"Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation","volume":"74","author":"Harvey","year":"2003","journal-title":"J. Leukoc. Biol."},{"issue":"3","key":"10.1016\/j.cyto.2016.07.004_b0140","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/hep.26788","article-title":"Hepatic interferon-stimulated genes are differentially regulated in the liver of chronic hepatitis C patients with different interleukin-28B genotypes","volume":"59","author":"Honda","year":"2014","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"4","key":"10.1016\/j.cyto.2016.07.004_b0145","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood-2005-01-0126","article-title":"Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C","volume":"106","author":"Butera","year":"2005","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.cyto.2016.07.004_b0150","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1002\/hep.21407","article-title":"IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection","volume":"44","author":"Lagging","year":"2006","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"7","key":"10.1016\/j.cyto.2016.07.004_b0155","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1086\/507307","article-title":"Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection","volume":"194","author":"Romero","year":"2006","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.cyto.2016.07.004_b0160","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/hep.24056","article-title":"Quantitation of pretreatment serum interferon-gamma-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response","volume":"53","author":"Darling","year":"2011","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"2","key":"10.1016\/j.cyto.2016.07.004_b0165","doi-asserted-by":"crossref","first-page":"e17232","DOI":"10.1371\/journal.pone.0017232","article-title":"Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms","volume":"6","author":"Lagging","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.cyto.2016.07.004_b0170","article-title":"Serum interferon-gamma-inducible protein-10 concentrations and IL28B genotype associated with responses to pegylated interferon plus ribavirin with and without telaprevir for chronic hepatitis C","author":"Matsuura","year":"2013","journal-title":"Hepatol. Res.: Official J. Jpn. Soc. Hepatol."},{"key":"10.1016\/j.cyto.2016.07.004_b0175","doi-asserted-by":"crossref","DOI":"10.1111\/hepr.12326","article-title":"Clinical significance of pretreatment serum interferon-gamma-inducible protein 10 concentrations in chronic hepatitis C patients treated with telaprevir-based triple therapy","author":"Nishikawa","year":"2014","journal-title":"Hepatol. Res.: Official J. Jpn. Soc. Hepatol."},{"issue":"8","key":"10.1016\/j.cyto.2016.07.004_b0180","first-page":"407","article-title":"IP-10 in chronic hepatitis C patients treated with high-dose interferon","volume":"72","author":"Willemse","year":"2014","journal-title":"The Netherlands J. Med."},{"issue":"1","key":"10.1016\/j.cyto.2016.07.004_b0185","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jhep.2011.07.016","article-title":"Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan","volume":"56","author":"Kumada","year":"2012","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.cyto.2016.07.004_b0190","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1159\/000086064","article-title":"Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy","volume":"48","author":"Akuta","year":"2005","journal-title":"Intervirology"},{"issue":"6","key":"10.1016\/j.cyto.2016.07.004_b0195","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"5","key":"10.1016\/j.cyto.2016.07.004_b0200","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1128\/JCM.02139-10","article-title":"The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon\/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B","volume":"49","author":"Ito","year":"2011","journal-title":"J. Clin. Microbiol."},{"issue":"5","key":"10.1016\/j.cyto.2016.07.004_b0205","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/hep.23509","article-title":"Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C","volume":"51","author":"Askarieh","year":"2010","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"5","key":"10.1016\/j.cyto.2016.07.004_b0210","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1002\/hep.21853","article-title":"Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response","volume":"46","author":"Feld","year":"2007","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"1","key":"10.1016\/j.cyto.2016.07.004_b0215","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/hep.24623","article-title":"Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response","volume":"55","author":"Asahina","year":"2012","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"5","key":"10.1016\/j.cyto.2016.07.004_b0220","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jhep.2007.04.009","article-title":"The role of CCR5\/CXCR3 expressing CD8+ cells in liver damage and viral control during persistent hepatitis C virus infection","volume":"47","author":"Larrubia","year":"2007","journal-title":"J. Hepatol."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466616301600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466616301600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T20:50:13Z","timestamp":1760907013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466616301600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":44,"alternative-id":["S1043466616301600"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2016.07.004","relation":{},"ISSN":["1043-4666"],"issn-type":[{"type":"print","value":"1043-4666"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pretreatment serum levels of interferon-gamma-inducible protein-10 are associated with virologic response to telaprevir-based therapy","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2016.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}